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During stroke the blood-brain barrier (BBB) is damaged which can result in vasogenic brain 
edema and inflammation. The reduced blood supply leads to decreased delivery of oxygen 
and glucose to affected areas of the brain. Oxygen and glucose deprivation (OGD) can cause 
upregulation of glucose uptake of brain endothelial cells. In this letter, we investigated the 
influence of MK801, a non-competitive inhibitor of the NMDA-receptor, on the regulation of 
the glucose uptake and of the main glucose transporters glut1 and sglt1 in murine BBB cell 
line cerebEND during OGD. mRNA expression of glut1 was upregulated 68.7-fold after six 
hours OGD, which was significantly reduced by 10 µM MK801 to 28.9-fold. Sglt1 mRNA 
expression decreased during OGD which was further reduced by MK801. Glucose uptake was 
significantly increased up to 907% after six hours OGD and was still higher (210%) after the 
20 hours reoxygenation phase compared to normoxia. Ten µM MK801 during OGD was able 
to reduce upregulated glucose uptake after OGD and reoxygenation significantly. Presence of 
several NMDAR subunits was proven on the mRNA level in cerebEND cells. Furthermore, it 
was shown that NMDAR subunit NR1 was upregulated during OGD and that this was 
inhibitable by MK801. In conclusion, the addition of MK801 during the OGD phase reduced 
significantly the glucose uptake after the subsequent reoxygenation phase in brain endothelial 
cells.  
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The main fuel for the brain is glucose. Glucose is mainly transported by the highly 
glycosylated 55 kDa form of the sodium independent, facilitative glucose transporter glut1 
across the blood-brain barrier (BBB) into the CNS [22]. During stroke the reduction of blood 
supply results in a decrease of oxygen and glucose in local areas of the brain. Ischemia 
followed by reperfusion leads to BBB disruption and the increased cerebrovascular 
permeability contributes to vasogenic brain edema and inflammation [1,9] which can 
influence the stroke outcome significantly. Glucose transporters are upregulated by hypoxia 
as well as aglycemia in several tissues and cell types [13]. This upregulation is potentiated 
when oxygen and glucose deprivation (OGD) is applied in combination at the same time. The 
therapeutical approaches for stroke are limited. Recently, Espinoza-Rojo et al. [6] suggested 
to investigate glucose transporter as novel targets for the treatment of stroke. Since it is 
known that glucose transporters transport water together with glucose in order to compensate 
for the osmotic pressure [14,23,24], it was hypothesized that this co-transport of water may 
contribute to the formation of edema during stroke. Thus, it could be worthy to elucidate the 
underlying mechanisms leading to the upregulation of glut1 at the BBB. Four main incidents 
are known to cause glut1-upregulation: 1) glutamate excitotoxicity 2) hypoxia 3) aglycemia 
and 4) mitochondrial damage. Glutamate excitotoxicity and OGD can result in the formation 
of reactive oxygen species (ROS). ROS can cause mitochondrial damage [6]. In this context, 
it was recently reported that NMDAR inhibitor MK801 was able to block the upregulation of 
ROS formation and the following disruption of the barrier’s integrity after hypoxia or 
glutamate stimuli in in vitro BBB models [11,12]. Thus, the first aim of the presented work 
was to investigate our hypothesis that MK801 can reduce the upregulation of glut1 during 
OGD in brain endothelial cells and to elucidate the contribution of this inhibition onto the 
total glucose uptake. Recently, presence and upregulation of sodium coupled glucose 




transporter 1 (sglt1) during OGD was reported in bovine brain endothelial cells [23]. 
Furthermore, functionality of sglts in BBB models was shown in vitro and an important role 
for sglts in vivo in edema formation during stroke was suggested [15,23]. However, sglt 
functionality at the BBB under physiological conditions is under doubt [25]. Consequently, 
we included sglt1 in our investigations and tested presence and regulation of sglt1 in our BBB 
model based on murine cell line cerebEND [20]. For our BBB in vitro model we have chosen 
to use cerebEND cells since they possess key BBB properties and markers, were tighter and 
exhibit an increased sensitivity to stimuli in comparison to other BBB in vitro models based 
on cell lines [18,20].  
 
Material and Methods 
 
Murine brain endothelial cell line cerebEND was generated from isolated brain microvascular 
endothelial cells from mouse cerebellum by Silwedel and Foerster [20]. cerebENDs were 
cultured in DMEM medium supplemented with 10 % FCS and 1 % penicillin/streptomycin 
onto gelatine coated cell culture tissue flasks and were subcultivated by trypsination in a ratio 
of 1:3 once a week. Cells were maintained in an incubator at 37°C, 95% humidity and a 5% 
CO2/95% air atmosphere. For mRNA as well as glucose uptake studies cerebENDs were 
seeded at a density of 20,000 cells/cm2 in gelatine-coated 6-well plates and were grown to 
confluence within 5 days of culture. On day 5 after seeding serum amount of the growth 
medium was reduced to 1 % FCS-SS in DMEM to enhance differentiation of the cells. On the 
next day oxygen/glucose deprivation (OGD) was applied on cerebEND cells in an InVivo2 
hypoxia work station (Ruskinn) with 0.5 % O2, 5 % CO2, saturated humidity atmosphere and 
37 °C for 6 hours [9]. After the OGD phase cells were immediately used for mRNA analysis 
or glucose uptake studies or a subsequent 20 hour reoxygenation phase was accomplished. 
MK801 was only added during the 6 h OGD phase to the growth media.  




For mRNA analysis cells were lysed and RNA was isolated using the RNeasy Mini Kit 
(Quiagen) according to the manufacturer instructions. mRNA for qPCR analysis of glut1 and 
NMDAR subunits NR1, NR2A, NR2B, N2C, NR2D, NR3A and NR3B was reverse 
transcribed into cDNA by means of the Verso-kit (ThermoScientific) using oligodT primers 
according to the manufacturer’s instruction. For cDNA synthesis of low abundant target sglt1 
the high capacity cDNA-kit from Applied Biosystems was applied followed by a cDNA 
preamplification step before qPCR was conducted. 0.85 µg total RNA per sample were 
transcribed to 20 µL cDNA. cDNA for 18SrRNA and sglt1 was then preamplified according 
to the protocol provided by Applied Biosystems. qPCR analysis were performed using either 
Taqman® probes (Applied Biosystems) for glut-1 (Mm01192270_m1), sglt1 
(Mn01218039_m1) and 18SrRNA (endogenous control, EUK18SrRNA, 4352930-0810022) 
or primers from MWG Eurofins with SYBRGreen for NR1 
(fw:CTCTAGCCAGGTCTACGCTATCC, rev:GACGGGGATTCTGTAGAAGCCA; 
specific for all 3 transcript variants, accession numbers: NM_001177657.1; 
NM_001177656.1; NM_008169.2), NR2A (fw:ACATCCACGTTCTTCCAGTTTGG, 
rev:GACATGCCAGTCATAGTCCTGC; NM_008170.2), NR2B 
(fw:CCAGAGTGAGAGATGGGATTGC, rev:TGGGCTCAGGGATGAAACTGT; 
NM_008171.3), NR2C (fw:GGGCTTCTGCATCGACATCC, 
rev:ATCATACCATTCCACACACCACG; NM_010350.2), NR3A 
(fw:ATCCTCAAGCGCATCGGACA, rev:CGACTCTGGCTCATCCCTCTG; 
NM_001033351.1), NR3B (fw:GGCCGTGACCAGCTTCAGTA, 
rev:CAATGGGTGAGGCTGTATCTCG; NM_130455.2) and 18SrRNA 
(fw:ATGGTTCCTTTGGTCGCTCG, rev:GAGCTCACCGGGTTGGTTTT; NR_003278.2) 
in 25 µL total volume per well. All qPCR analysis were conducted by means of a 7300 Real-
Time PCR System (Applied Biosystems). Each sample was analyzed as triplicate. Relative 
mRNA abundances to 18 SrRNA were calculated by the dCt method using following formula: 




2(Ct of 18 S rRNA-Ct of gene of interest), where Ct is the threshold cycle value. For the qualitative proof 
of the presence of NMDAR subunits cDNA samples amplification products were separated on 
a 2 % agarose gel in TAE-buffer with a peqGOLD 50 bp DNA-ladder as marker at 90 V for 
half an hour.  
For glucose uptake studies cell layers were washed with prewarmed PBS twice and were 
preincubated with PBS (with Ca2+/Mg2+) containing glucose transporter inhibitors (10 µM 
phloretin for glut-1 blockade, 20 mM galactose for sglt1 blockade) at 37°C for 20 minutes. 
After preincubation 50 µM [3H]-glucose (1 mCi/mL, 50-60 Ci/mmol, 0113A, ARC) 
supplemented with inhibitors were added. After 15 minutes at 37°C cell layers were washed 
with ice-cold PBS for three times. Cells were then lysed with 1 % Triton-X 100 solution and 
lysates were added to 3097 Lumasafe plus solution (Lumac-lsc B.V.) to measure radioactivity 
by a beta-counter LS 6500 (Beckman). Each sample was determined as triplicate and at least 
three samples were collected for each condition (n=3). Resulted dpm values were normalized 
to according sample’s protein content (Pierce BCA assay, Thermo Scientific) and were related 
to appropriate normoxic controls which were set to 100 % and to radioactivity of each applied 
stock solution. For cell viability tests (EZ4U, Biomedica) cerebENDs were seeded in gelatine-
coated 96-well microplates and were treated under the same OGD conditions as explained 
above. Cell viability tests were carried out according to the manufacturer’s instruction. Details 
of the methods are described in the electronic supplementary file available on the Journal’s 
website.  
 




Results and Discussion 
 
The main glucose transporter in brain capillary endothelial cells is glut1 [22]. Thus, the 
regulation of glut1 in murine cerebEND cells was investigated during normoxic, hypoxic and 
OGD conditions. Cell viability measurements revealed no cytotoxic effect independent of 
each treatment modality on cerebEND cells (data not shown). Results shown in figure 1 
clearly showed the upregulation of glut1 during the six hours under hypoxic and OGD 
conditions compared to the normoxic experiment. For example, glut1 was upregulated after 
six hours during hypoxia 15.4-fold (p<0.001) and 68.7-fold (p<0.001) during OGD. This 
ranking order of differential answers to different hypoxia/aglycemia stimuli was completely in 
concordance to results of Abbruscato and Davis [1] who showed that the permeability of a 
blood-brain barrier in vitro model increased stepwise dependent on application of aglycemia, 
hypoxia and OGD. Addition of MK801 decreased glut1 mRNA expression during hypoxia 
and OGD. For example, presence of 10 µM MK801 during OGD reduced significantly glut1 
upregulation from 68.7 to 28.9-fold (p<0.05). During hypoxia MK801 decreased glut1 
expression in a concentration dependent manner, whereby addition of 1 µM MK801 yielded 
in the most distinct, but not significant effect and reduced glut1 expression from 15.4 to 11.4-
fold compared to normoxia. Addition of MK801 during OGD revealed no significant 
differences after subsequent reoxygenation in comparison to the appropriate hypoxia and 
OGD samples.  
Since strongest effects on glut1 regulation were found after OGD, further investigations were 
done under OGD conditions. Recently, presence and functional relevance of a second glucose 
transporter at the BBB, called sglt1, was reported [4,15,23]. Results shown in figure 2 
revealed that mRNA of sglt1 was significantly downregulated during six hours of OGD (0.57-
fold, p<0.001) compared to according normoxia samples. Addition of 1 µM MK801 reduced 
sglt1 expression to 49%, which was further decreased by 10 µM MK801 to 45% after OGD in 




comparison to normoxia (p<0.001; but not statistically significant compared to OGD). After 
the additional reoxygenation sglt1 expression of the OGD treated cells approximated to the 
corresponding normoxia controls. Only treatment during OGD with 10 µM MK801 revealed 
significantly lower sglt1 expression than normoxic controls (p<0.05).  
As next step we investigated if murine blood-brain barrier cell line cerebEND expresses 
NMDA receptor subunits and whether their expression could also be regulated by addition of 
their blocker MK801. First, presence of NMDAR subunit transcripts of NR1, NR2A, NR2B, 
NR2C, NR3A and NR3B was proven by PCR (figure 3A). A conventional, functionally active 
NMDAR has to possess NR1 subunits. Furthermore, Reijerkerk et al. [19] confirmed a 
relevant role of the NR1 subunit at the BBB in vitro during monocyte migration. 
Consequently, we analyzed whether mRNA expression of NR1 had been regulated during 
OGD and if this was influenced by NMDAR blocker MK801. Results depicted in figure 3B 
revealed a distinct upregulation of NR1 during OGD and that this was counterregulated by 
NMDAR inhibitor MK801. In detail, NR1 mRNA was upregulated after six hours OGD up to 
2.9-fold in comparison to normoxia which persisted at a level of 3.1-fold after the additional 
20 hours of reoxygenation (both p<0.05). MK801 was able to decrease NR1 upregulation 
during OGD and reduced NR1 expression after additional 20 hours reoxygenation to 1.66- (10 
µM MK801, p>0.05) and 0.68-fold (100 µM MK801, p<0.05).  
Our presented findings here showed significant upregulation of glucose transporter glut1 and 
NR1 after OGD and a reduction of their upregulation by addition of MK801. However, no 
complete blockade of the upregulations was achieved by MK801. Thus, in order to investigate 
the functional relevance of regulated mRNA expression of glucose transporters glut1 and 
sglt1, glucose uptake studies were accomplished. It was decided to add 10 µM MK801 during 
OGD since this concentration of MK801 exhibited the strongest inhibitory effects on glut1 
and sglt1 mRNA expression after 6 hours OGD. Figure 4 shows that glucose uptake was 
significantly increased up to 907 ± 69 % (p<0.05) directly after six hours of OGD treatment. 




After a following 20 hours reoxygenation phase glucose uptake was still significantly higher 
(210 ± 12 %, p<0.05) than the normoxia control. Addition of 10 µM MK801 reduced glucose 
uptake to 845 ± 20 % measured directly after OGD (statistically not significant) and 
significantly decreased it to 163 ± 9 % after the additional reoxygenation phase (p<0.05). To 
elucidate the roles of glut1 and sglt1 in the glucose uptake rates phloretin, a glut1 inhibitor 
[7], and galactose, a sglt1 inhibitor [3], were added during the uptake studies. Directly after 
OGD 10 µM phloretin significantly reduced the uptake of glucose to 170 ± 4 % (p<0.05), 
whereas supplementation of 20 mM galactose revealed a moderate, but also significant 
decrease to 657 ± 14 % (p<0.05). Interestingly, phloretin still decreased glucose uptake after 
the additional reoxygenation phase from 210 ± 13 % to 57 ± 2 % (p<0.05), whereas galactose 
only reduced the glucose uptake to 174 ± 12 %. These results indicated that both transporters 
glut1 and sglt1 contributed to the increased glucose uptake during OGD. This was in 
concordance to first studies of Matsuoka et al. [15] showing functional presence of sglts at the 
BBB in vitro. In order to assign the reducing effects of MK801 on glucose uptake during 
OGD specifically to single glucose transporters, their regulation on the protein level has to be 
studied and known non-genomic mechanisms of the regulation of the transporter’s 
functionality have to be included into the considerations [10]. These regulatory processes at 
the protein level are probably responsible for possible discrepancies between our observations 
on the mRNA and on the functional level. Western blots showed the up-regulation of glut1 
and sglt1 in cerebENDs after OGD and reoxygenation on the protein level (see supplementary 
figure 1) supporting our glucose uptake results and confirming data from the literature that 
glucose transporters are posttranscriptionally regulated by processes which can control 
mRNA stability, transporter concentrations at the luminal surface and their affinities to 
glucose [6,21]. Furthermore, presence and function of other glucose transporters at the BBB 
should not be neglected. For example, Enerson and Drewes [5] reported presence of mRNA 
of the glucose transporter sglt2 in rat brain capillaries. However, in our present report we 




show that glut1 expression is affected by different glucose/oxygen conditions in the murine 
blood-brain barrier cell line cerebEND and that the expression of glut1 can be influenced by 
NMDAR blocker MK801. Furthermore, to our best knowledge we are the first who report the 
presence of several NMDAR subunits in cerebEND cells and the significant upregulation of 
NR1 during OGD and that this can be blocked by NMDAR inhibitor MK801. Moreover, we 
were able to prove the hypothesis that MK801 is able to decrease the upregulation of glucose 
transporter glut1 during OGD and to reduce the elevated glucose uptake after OGD. However, 
the direct link between the regulation of glucose transporters and NMDAR is not fully 
resolved. Hypoxia leads to an increase of the intracellular Ca-level by influx of extracellular 
Ca-ions as well as by a Ca-release from intracellular stores at the BBB in vitro, and Ca-
signalling under hypoxia plays a crucial role for the formation of ROS [12]. Then, ROS 
damage membranes of mitochondria impairing oxidative phosphorylation which result in the 
upregulation of glucose transporters [6]. Under hypoxia astrocytes play an important role in 
these processes since they release glutamate to e.g. modulate NMDAR functionality or VEGF 
to stimulate glut1 expression via HIF-1 and HRE elements [6,12]. Interestingly, in the present 
work we have observed effects by MK801 in our BBB in vitro model without using astrocytes 
indicating the presence of alternative pathways. Recently, deleterious effects of homocysteine 
onto the BBB were reported to be mediated by NMDAR [2]. Furthermore, we and others were 
able to show that MK801 alone can affect the proteome and the intracellular Ca-level of BBB 
models [16,17]. Consequently, it should be taken into consideration that currently unknown 
serum components may act as NMDAR agonists or that MK801 can affect the intracellular 
Ca-level without prior NMDAR stimulation which can lead to decreased ROS formation and 
subsequent lower glucose transporter functionality.  
In conjunction with the postulated co-transport of water and glucose molecules [14], the 
treatment with NMDAR-antagonists may result in reduced edema formation after stroke. In 
this context, further studies concerning NMDAR functionality and underlying signalling 




pathways involved in the treatment with NMDAR antagonists at the BBB are required in 
order to identify suitable downstream targets for future stroke therapies.  
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Figure legends  
 
Figure 1: Concentration dependent regulation of glut1 mRNA in cerebEND cells by MK801 
during six hours hypoxia and OGD and subsequent 20 hours reoxygenation (RO). Data are 
presented as means ± SEM (n=5-9). Statistically significant differences are marked by * 
(p<0.05, two-sided t-test with same variances) and ** (p<0.001, two-sided t-test with same 
variances) in comparison to normoxia and # (p<0.05, two-sided t-test with same variances) in 
comparison to OGD conditions.  
 
Figure 2: Concentration dependent regulation of sglt1 mRNA in cerebEND cells by MK801 
during six hours OGD and a subsequent 20 hours reoxygenation (RO) phase. Data are 
presented as means ± SEM (n=6-9). Statistically significant differences are marked by * 
(p<0.05, two-sided t-test with same variances) and ** (p<0.001, two-sided t-test with same 
variances) in comparison to normoxia. 
 
Figure 3: Presence of NMDAR-subunits (NR1: 106 bp, NR2A: 87 bp, NR2B: 81 bp, NR2C: 
120 bp, NR3A: 132 bp, NR3B: 119 bp) in cerebEND cells (A) and the concentration 
dependent regulation of subunit NR1 by MK801 during six hours OGD and additional 20h 
reoxygenation (RO) phase (B). Data are presented as means ± SEM (n=5-9). Statistically 
significant differences are marked by * (p<0.05, two-sided t-test with same variances) in 
comparison to normoxia and by # (p<0.05, two-sided t-test with same variances) in 
comparison to OGD conditions. 
 
Figure 4: Increased [3H]-glucose uptake of cerebEND cells after six hours OGD and 
subsequent 20 hours reoxygenation (RO) is blocked by 10 µM phloretin (PT, glut1-inhibitor) 
and 20 mM galactose (GAL, sglt1-inhbitor). Addition of 10 µM MK801 during 6h OGD 




phase reduces the glucose uptake after the reoxgenation phase significantly. Data are 
presented as means ± SEM (n=3). Statistically significant differences are marked by * 
(p<0.01, two-sided t-test with same variances) in comparison to normoxia and by # (p<0.05, 
two-sided t-test with same variances) in comparison to OGD conditions.  
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